# A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

> **NCT05429593** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 152 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Dapagliflozin
- **DRUG:** Semaglutide/dapagliflozin

## Key facts

- **NCT ID:** NCT05429593
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-22
- **Primary completion:** 2023-03-10
- **Final completion:** 2023-04-13
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429593, "A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05429593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*